⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700765 | 0.74 | — | — | |
| SCHEMBL25112082 | 0.70 | — | — | |
| SCHEMBL1092933 | 0.70 | — | — | |
| SCHEMBL24818436 | 0.70 | — | — | |
| SCHEMBL589096 | 0.70 | — | — | |
| SCHEMBL27893005 | 0.70 | — | — | |
| SCHEMBL20485653 | 0.70 | — | — | |
| SCHEMBL26011730 | 0.70 | CA1 (0.46) | — | |
| SCHEMBL16010348 | 0.70 | CA1 (0.46) | — | |
| SCHEMBL21282786 | 0.70 | GPR84 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2020-12-17 | — | — | US | disclosed |
| US-9051316-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2132206-B1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2015-04-01 | — | — | EP | disclosed |
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140100243-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE AMIDES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| US-8436180-B2 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8344118-B2 | Preparation and isolation of 5′ capped MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100136142-A1 | SUBSTITUTED-4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | BAYER SCHERING PAHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-03 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2132206-A2 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009058911-A2 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-2029591-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008104306-A2 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007140934-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |